What’s Trending on Twitter Regarding the Most Recently Approved Oral Agent for HIV Pre-Exposure Prophylaxis (PrEP)?
Introduction: Pre-exposure prophylaxis (PrEP) is a key therapeutic strategy for HIV prevention. Descovy® is the most recently approved oral agent for PrEP. Despite availability, there continues to be suboptimal PrEP use among at-risk individuals. Social media platforms have a role in disseminating health information, to include education on PrEP.
Material and methods: A content analysis was conducted of “tweets” posted on Twitter® during the initial year of Descovy’s FDA approval for PrEP. The coding schema captured content related to the indication, appropriate use, costs, and safety profile of Descovy.
Results: Most tweets provided information on target population, dosing strategy, and side effects of Descovy. Information on costs and appropriate use was frequently missing.
Conclusion: Health educators and providers should be aware of gaps in social media messaging concerning PrEP and should educate patients to ensure they are well informed when considering PrEP.
Copyright (c) 2022 Alexandria Boot, Crystal Deas
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).